• 00Days
  • 00Hrs
  • 00Mins
  • 00Secs

Marrion Pharma Inc.

Marrion Pharma Inc is a dynamic pharmaceutical distribution company committed to meeting
the unique needs of the Ophthalmology market in the Philippines. Our dedication to excellence
and innovation positions us as a leading provider of visionary healthcare solutions. We take
pride in our recent entry into the market and our aspirations to expand our reach nationwide.

Company History:
Founded 2006, Marrion Pharma has rapidly evolved, achieving milestones that reflect our
dedication to advancing eye health in the Philippines.

Specializing in Ophthalmology, Marrion Pharma delivers a comprehensive range of
pharmaceutical products tailored to address the diverse requirements of eye care professionals.
Our offerings encompass cutting-edge solutions designed to enhance vision and improve ocular

Core Values:
At Marrion Pharma, integrity, quality, and a patient-centric approach form the core of our
values, driving us to provide the highest standard of eye care solutions.

Our team comprises seasoned professionals with a wealth of experience in the pharmaceutical
industry, united by a passion for improving lives through visionary healthcare solutions.

Quality Assurance:
Marrion Pharma upholds rigorous quality assurance standards to ensure that every product
reaching our clients maintains the highest levels of safety and efficacy.

Customer Base:
Marrion Pharma proudly serves as a trusted partner to major hospitals and prominent eye
centers in key cities across the Philippines. Our collaborations with esteemed healthcare
institutions underscore our commitment to delivering unparalleled eye care solutions.

Expansion Plans:
Having established a strong presence in key cities, Marrion Pharma is now poised for
nationwide expansion. Our strategic vision involves reaching every corner of the Philippines,
bringing world-class eye care solutions to communities far and wide.


Abstract submission deadline extended

Important dates
Submission open: NOW!
Submission close: 1 Dec 2023 Monday 15 January 2024
Author notifications: 15 February 2024